This data indicates that strong AP activation can be suppressed by inhibiting properdin, while it overwhelms the ability of eculizumab to protect, similar to what was observed with PNH patients under eculizumab treatment. Here, CFP is linked to paroxysmal nocturnal hemoglobinuria.